Approval · Notice of Compliance 10373 · 2009
PRIVIGEN: Notice of Compliance 10373
Issued July 10, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10373
- Date
- July 10, 2009
- Company
- Csl Behring Canada IncOttawa, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Increased infusion rate to a maximum of 12mg/kg/min, when tolerated by the patient
- Therapeutic class
- Passive immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIVIGEN | Not yet assigned | — |
Medicinal ingredients
- IMMUNOGLOBULIN (HUMAN) 10 PER